|
[1]JIN Y, LI JT.Research progress in related clinical factors and molecular biomarkers for microvascular invasion in hepatocellular carcinoma[J].J Clin Hepatol, 2013, 29 (7) :550-553. (in Chinese) 金赟, 李江涛.肝癌细胞侵犯微血管的临床相关因素及分子标志物的研究进展[J].临床肝胆病杂志, 2013, 29 (7) :550-553.
|
|
[2] LLOVET JM.Updated treatment approach to hepatocellular carcinoma[J].J Gastroenterol, 2005, 40 (3) :225-235.
|
|
[3] ANDO E, TANAKA M, YAMASHITA F, et al.Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis:analysis of 48 cases[J].Cancer, 2002, 95 (3) :588-595.
|
|
[4]ZHANG Y, ZHANG JW, LYU GY, et al.Effects of STAT3 gene silencing and rapamycin on apoptosis in hepatocarcinoma cells[J].Int J Med Sci, 2012, 9 (3) :216-224.
|
|
[5] BHASKAR PT, HAY N.The two TORCs and Akt[J].Dev Cell, 2007, 12 (4) :487-502.
|
|
[6]ENGELMAN JA.Targeting PI3K signalling in cancer:opportunities, challenges and limitations[J].Nat Rev Cancer, 2009, 9 (8) :550-562.
|
|
[7]ENGELMAN JA, LUO J, CANTLEY LC.The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism[J].Nat Rev Genet, 2006, 7 (8) :606-619.
|
|
[8]PENE F, CLAESSENS YE, MULLER O, et al.Role of the phosphatedylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma[J].Oncogene, 2002, 21 (43) :6587-6597.
|
|
[9] KATSO R, OKKENHAUG K, AHMADI K, et al.Cellular function of phosphoinositide 3-kinases implications for development, homeostasis, and cancer[J].Annu Rev Cell Dev Biol, 2001, 17 (4) :615-675.
|
|
[10] HILL MM, HEMMINGS BA.Inhibition of protein kinase B/Akt implycations for cancer therapy[J].Pharmacol Ther, 2002, 93 (2/3) :243-251.
|
|
[11]HUANG J, MANNING BD.The TSC1-TSC2 complex:a molecular switchboard controlling cell growth[J].Biochem J, 2008, 412 (2) :179-190.
|
|
[12]WAN X, HELMAN LJ.The biology behind mTOR inhibition in sarcoma[J].Oncologist, 2007, 12 (8) :1007-1018.
|
|
[13] JIANG BH, LIU LZ.PI3K/PTEN signaling in angiogenesis and tumorigenesis[J].Adv Cancer Res, 2009, 102:19-65.
|
|
[14]MAMANE Y, PETROULAKIS E, LEBACQUER O, et al.mTOR, translation initiation and cancer[J].Oncogene, 2006, 25 (48) :6416-6422.
|
|
[15] GUERTIN DA, SABATINI DM.An expanding role for mTOR in cancer[J].Trends Mol Med, 2005, 11 (8) :353-361.
|
|
[16]BANUMATHY G, CAIRNS P.Signaling pathways in renal cell carcinoma[J].Cancer Biol Ther, 2010, 10 (7) :658-664.
|
|
[17] DURONIN V.The life of a cell:apoptosis regulation by the PI3K/PKB pathway[J].Biochem J, 2008, 415 (3) :333-344.
|
|
[18]LIU LX, LIU ZH, JIANG HC, et al.Gene expression profiles of hepatoma cell line HLE[J].World J Gastroenterol, 2003, 9 (4) :683-687.
|
|
[19] SUZUKI Y, TOQUENAGA Y.Effects of information and group structure on evolution of altruism:analysis of two-score model by covariance and contextual analyses[J].J Theor Bio, 2005, 232 (2) :191-201.
|
|
[20] MICHL P, DOWNWARD J.Mechanisms of disease:PI3K/AKT signaling in gastrointestinal cancers[J].Z Gastroenterol, 2005, 43 (10) :1133-1139.
|
|
[21]TUCK AB, HOTA C, WILSON SM, et al.Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways[J].Oncogene, 2003, 22 (8) :1198-1205.
|
|
[22] MOTTET D, DUMONT V, DECEACHE Y, et al.Regulation of hypoxia-inducible factor-1 alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells[J].J Biol Chem, 2003, 278 (33) :31277-31285.
|
|
[23]LIU L, ZHU S, GONG I, et al.K-ras/PI3K-Akt signaling is essential for zebrafish hematopoiesis and angiogenesis[J].PLos One, 2008, 3 (8) :e2850.
|
|
[24] GORDAN JD, SIMON MC.Hypoxia-inducible factors:central regulators of the tumor phenotype[J].Curr Opin Genet Dev, 2007, 17 (1) :71-77.
|
|
[25]JIANG BH, LIU LI.AKT signaling in regulating angiogenesis[J].Curr Cancer Drug Targets, 2008, 8 (1) :19-26.
|
|
[26]MOTTET D, DUMONT V, DECCACHE Y, et al.Regulation of hypoxia-inducible factor-1 alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells[J].J Biol Chem, 2003, 278 (33) :31277-31285.
|
|
[27]ARSHAM AM, PLAS DR, THOMPSON CB, et al.Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis[J].Cancer Res, 2004, 64 (10) :3500-3507.
|
|
[28]OHTA T, OHMICHI M, HAYASAKA T, et al.Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models[J].Endocrinology, 2006, 147 (4) :1761-1769.
|
|
[29]GERA JF, MELLINGHOFF IK, SHI Y, et al.AKT activity determines sensitivity to mammalian target of rapamyein (mTOR) inhibitors by regulating cyclin D1 and c-myc expression[J].J Biol Chem, 2004, 279 (4) :2737-2746.
|
|
[30]JUNG KH, ZHENG HM, JEONG Y, et al.Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor[J].Cancer Lett, 2013, 328 (1) :176-187.
|
|
[31] CHANG Z, SHI G, JIN J, et al.Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced byinhibitors of autophagy[J].Int J Mol Med, 2013, 31 (6) :1449-1456.
|
|
[32]LEE JH, LEE H, YUN SM, et al.IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma[J].Cancer Lett, 2013, 329 (1) :99-108.
|
|
[33]SIMIONI C, MARTELLI AM, CANI A, et al.The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy[J].Oncotarget, 2013, 4 (9) :1496-1506.
|
|
[34]MEUILLET EJ, IHLE N, BAKER AF, et al.In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316[J].Oncol Res, 2004, 14 (10) :513-527.
|
|
[35] ZHANG M, FANG X, LIU H, et al.Blockade of AKT activation in prostate cancer cells with a small molecule inhibitor, 9-chloro-2-methylellipticinium acetate (CMEP) [J].Biochem Pharmacol, 2007, 73 (1) :15-24.
|
|
[36] SEMELA D, PIGUET AC, KOLEV M, et al.Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma[J].J Hepatology, 2007, 46 (5) :840-848.
|
|
[37]DANCEY JE.Inhibitors of the mammalian target of rapamycin[J].Expert Opin Investig Drugs, 2005, 14 (3) :313-328.
|
|
[38] KNOWLES MA, PLATT FM, ROSS RL, et al.Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer[J].Cancer Metastasis Rev, 2009, 28 (3-4) :305-316.
|
|
[39] KIRSTEIN MM, BOUKOURIS AE, POTHIRAJU D, et al.Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma[J].Liver Int, 2013, 33 (5) :780-793.
|
|
[40]FUEREDER T, JAEGER A, HOEFLMAYER D, et al.mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves antitumor activity against gastric cancer in vivo[J].Cancer Lett, 2010, 296 (2) :249-256.引证本文:YU Y, CHEN XR.Role of PI3K/Akt/mTOR signaling pathway in hepatocellular carcinoma[J].J Clin Hepatol, 2014, 30 (9) :954-957. (in Chinese) 俞媛, 陈晓蓉.PI3K/Akt/mTOR信号转导通路在肝细胞癌发生发展中的作用[J].临床肝胆病杂志, 2014, 30 (9) :954-957.
|
DownLoad: